Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 07 - 01 tags : Trial save search
Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Published: 2021-07-01 (Crawled : 00:00) - biospace.com/
ALRN | $4.75 4.04% 68K
|
Health Technology
|
| O: 2.4%
H: 2.34%
C: 2.34%
lung cancer cancer trial
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned
Published: 2021-07-01 (Crawled : 22:00) - biospace.com/
CTXR | $0.7673 4.51% 4.9% 630K
|
Health Technology
|
| O: -16.81%
H: 10.19%
C: -10.19%
positive phase 3 trial
STAG Industrial To Report Second Quarter 2021 Results
Published: 2021-07-01 (Crawled : 21:00) - stagindustrial.com
STAG | $35.41 0.2% -0.48% 790K
|
Finance
|
| O: 0.56%
H: 0.67%
C: 0.43%
results trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Rocket Companies (RKT) Investors to Contact Firm's Attorneys Now, Securities Fraud Case Filed, Insider Sold Approximately $500MM
Published: 2021-07-01 (Crawled : 21:00) - prnewswire.com
RKT P | $12.63 5.51% -1.82% 1.7M
|
Finance
|
| O: -0.11%
H: 0.79%
C: -1.26%
trial
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
Published: 2021-07-01 (Crawled : 21:00) - biospace.com/
KRYS | News | $162.04 3.05% 3.04% 220K
|
Health Technology
|
| O: 0.76%
H: 5.59%
C: 4.74%
treatment biotech iot trial
Global Industrial PC Market to Reach $5.4 Billion by 2026
Published: 2021-07-01 (Crawled : 15:00) - prnewswire.com
ROK | News | $276.33 1.05% 0.05% 540K
|
Producer Manufacturing
|
| O: 0.7%
H: 0.0%
C: -0.94%
ABB | News | $37.13 -0.03% 6.4M
|
Producer Manufacturing
|
| O: 0.15%
H: 0.06%
C: -0.24%
trial market
Neonode Touch Sensor Modules Selected for Contactless Kiosk Trials by Global Airport Solution Provider in Japan
Published: 2021-07-01 (Crawled : 14:00) - prnewswire.com
NEON | $1.7 -11.0% -11.05% 95K
|
Technology Services
|
| O: 0.32%
H: 5.49%
C: 1.78%
sensor trial
Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer
Published: 2021-07-01 (Crawled : 14:00) - globenewswire.com
AVCO | $0.45 -16.15% 31.11%
|
Health Technology
|
| O: 2.8%
H: 0.99%
C: -1.64%
acquisition cancer brain cancer trial initiated train
Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
Published: 2021-07-01 (Crawled : 13:00) - biospace.com/
KTRA | $0.1327 16.1% 12.68% 7.4M
|
Distribution Services
|
| O: 11.01%
H: 13.1%
C: -8.73%
phase 2 results topline trial
Amyris Completes First Major License For Leading RNA Vaccine Advancing Technology To Human Trials
Published: 2021-07-01 (Crawled : 12:15) - prnewswire.com
AMRS | $0.05 -21.88% -16.36% 47M
|
Process Industries
|
| O: 1.34%
H: 3.01%
C: 2.41%
vaccine license technology trial
Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Published: 2021-07-01 (Crawled : 12:15) - globenewswire.com
RFL 4 | $1.71 -1.72% 0.0% 8.5K
|
Finance
|
| O: -0.39%
H: 7.81%
C: 6.78%
myeloid leukemia positive leukemia phase 3 trial cpi-613 acute myeloid leukemia aml
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
Published: 2021-07-01 (Crawled : 12:00) - biospace.com/
DTIL | $10.23 5.68% 6.29% 29K
|
Health Technology
|
| O: 1.04%
H: 1.74%
C: 0.08%
phase 1 trial car-t
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
Published: 2021-07-01 (Crawled : 12:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 600K
|
Health Technology
|
| O: -6.82%
H: 0.38%
C: -8.21%
phase 2 results cancer liver trial
Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
Published: 2021-07-01 (Crawled : 11:00) - globenewswire.com
ARQT | $8.74 -2.24% -2.35% 1.4M
|
Health Technology
|
| O: -2.93%
H: 3.16%
C: 0.04%
treatment phase 2 potential trial phase 2b
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.